Life sciences covers a wide range of companies with one thing in common: a regulated claim environment and a scientifically literate audience. A contract research organisation selling to biotech, a diagnostics company selling to hospital laboratories, a medical device manufacturer and a pharmaceutical company all buy digital marketing into constraints that consumer agencies never encounter. Sales cycles run for quarters, the buying group has several members with different questions, and every public claim passes a medical, legal and regulatory review. The agency that works here is the one that treats that review as part of the process rather than a hurdle to route around.
The audience is the constraint that shapes everything
Life sciences buyers are scientists, clinicians, procurement specialists and laboratory directors, and they read like scientists. Marketing copy that gestures at innovation without data is not merely ineffective with this audience, it is actively discrediting. That has practical consequences for the work: content needs citations, application notes and technical specifications matter more than brand narrative, and the most valuable asset is often a genuinely useful piece of technical documentation rather than a campaign. It also means the writer matters enormously. Ask a candidate agency who writes the technical content, what their scientific background is, and to show a piece they wrote in a comparable field. Copy in this sector cannot be produced by a generalist working from a briefing document.
Regulated claims and the review cycle
What a company may say about a product depends on what the product is and how it is regulated. Prescription drug advertising, for example, is governed by detailed requirements in the federal regulations covering the presentation of information about the drug, and device and diagnostic claims carry their own constraints tied to intended use and clearance status. Meanwhile any advertising claim, regulated or not, must be truthful and substantiated, and the FTC publishes compliance guidance on how health related benefit claims should be supported. The practical effect for a buyer is that the review cycle is the schedule. Tell candidates the realistic turnaround for medical, legal and regulatory review and watch how their plan changes. Agencies experienced here build a content calendar around review capacity; the others quote as though review does not exist.
What the digital programme actually looks like
Search visibility on technical and application terms is usually the highest value channel, because a scientist looking for a specific assay, instrument specification or service capability is expressing intent that no display campaign can manufacture. Technical content, meaning application notes, protocols, white papers and comparison pages, is what earns that visibility and what the sales team ends up sending to prospects anyway. Conference and event marketing remains genuinely important in this sector and should be integrated rather than treated separately. Email works well against an opted-in professional audience. Paid social works less well and is often the first line to cut. When scoping broader digital marketing and SEO services here, weight the budget toward search and technical content, because that is where a scientifically literate audience actually is.
How to vet an agency
Ask for two named clients in life sciences, ideally at your stage, and ask to speak to one about how review cycles were handled rather than about results. Ask who specifically writes and whether a subject matter expert reviews before your team sees a draft, because an agency that submits scientifically weak drafts will burn your reviewers' goodwill within two rounds. Ask for the disclosed minimum engagement and term in writing. Ask how the agency measures success in a market where a sales cycle outlasts most retainers, and expect a serious answer involving qualified enquiries, pipeline influence and engagement from target accounts rather than a promise about revenue in the first quarter.
Questions people ask about digital marketing for life sciences
Can a generalist agency do life sciences work?
Occasionally, if it hires or contracts genuine scientific writers and accepts the review process. Most cannot, and the failure shows up as drafts that reviewers reject repeatedly until the content calendar collapses. Test it cheaply: commission one paid piece on a technical topic before signing a retainer, and let your reviewers judge the draft.
How should success be measured with long sales cycles?
Use leading indicators tied to the buying group: qualified enquiries, engagement from named target accounts, technical content downloads by relevant job titles, and progression of opportunities that touched marketing content. Agree those before the engagement starts, because a retainer judged on closed revenue in quarter one will be judged unfairly and end early.
Who should own regulatory review of marketing content?
Your organisation, always. An agency can draft to guidance, flag risky claims and maintain a claims library, but the accountability for what publishes sits with the company whose product is promoted. Ask a candidate how it documents which claims were approved, in what version, so that reviewers are not re-litigating the same language every quarter.
Is paid search worth it for niche technical products?
Often yes, precisely because the audience is small and highly qualified. Volumes are low and click prices can be high, but a single qualified enquiry may be worth a large multiple of the campaign cost. Model it against your actual deal value and win rate rather than against generic benchmarks from consumer categories.